Cat. No. 5673
Chemical Name: 5-[[3-Methoxy-4-[(4-methoxyphenyl)m
Biological ActivityPotent and selective cFMS kinase inhibitor (IC50 = 0.06 μM). Exhibits selectivity for cFMS kinase over 186 other kinases. Inhibits CSF-1-induced growth of rat monocytes in vitro. Also inhibits bone resorption in osteoclast cultures, as well as connective tissue and bone destruction in a rat adjuvant arthritis model. Suppresses M-NFS-60 tumor cell growth in mice. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Conway et al (2008) Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J.Pharmacol.Exp.Ther. 326 41. PMID: 18434589.
Conway et al (2005) Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc.Natl.Acad.Sci.U.S.A. 102 16078. PMID: 16249345.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GW 2580 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: GW 2580, supplier, GW2580, cFMS, kinase, inhibitors, inhibits, CSF-1, colony-stimulating, factor, osteoclasts, arthritis, selective, orally, bioavailable, Tocris Bioscience, Other RTKs Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective TrkB receptor agonist; neuroprotectantAV 412
Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinasesCP 724714
Potent and selective ErbB2 inhibitorMitoglitazone
Insulin sensitizer; exhibits low binding affinity at PPARγPF 6274484
High affinity and potent covalent EGFR kinase inhibitorCanertinib dihydrochloride
Potent EGFR kinase inhibitorCHMFL-FLT3-122
Potent and selective FLT3 inhibitor
November 12 - 16, 2016
San Diego, CA, USA